Developer docs
API playgroundTry for free, no card

Search company profiles

Iantrek

Full company profile

uuid00005v6

Namestring
Iantrek
Legal namestring
Iantrek, Inc.
Websiteurl
iantrekmed.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Iantrek is a private medical technology company headquartered in White Plains, New York, that develops bio-interventional and micro-interventional ophthalmic surgical devices for the treatment of glaucoma. The company's commercial platform comprises three core products: AlloFlo Uveo, an acellular homologous scleral allograft bio-tissue spacer that reinforces the uveoscleral pathway to enhance aqueous outflow without damaging the conjunctiva or requiring implantable hardware; AlloSert Uveo, an ambidextrous surgical delivery instrument that enables controlled cyclodialysis and precise positioning of the AlloFlo Uveo dual bio-spacers; and C-Rex, a single-use disposable super-elastic Nitinol device for ab-interno transluminal canaloplasty and inner wall trabeculotomy, capable of 360-degree circumferential tracking in a single continuous motion. The platform is supported by the CREST clinical study (500+ eyes across 16 locations, 7 peer-reviewed publications) demonstrating 32–40% mean IOP reduction and 40–64% mean medication reduction at 12–24 months with sub-0.5% clinical hypotony rates.

Iantrek operates as a medical device manufacturer generating revenue through hardware and bio-tissue sales to ophthalmologists and glaucoma surgeons. Pricing is not publicly disclosed; transactions follow the standard institutional medtech quoting model. The go-to-market is enterprise field sales with a 'Contact a Rep' / 'Book a Demo' model targeting hospital and ambulatory surgical center accounts, supplemented by peer-reviewed publications, medical conference presence (ASCRS, AAO, AGS, Glaucoma 360, AECOS), surgeon testimonials, and a 'Find a Surgeon' patient-referral directory. The primary customer segment is MIGS-performing ophthalmologists and glaucoma specialists in the United States.

The company is venture-backed, having raised approximately $100 million cumulatively across a Series A (2020), Series B (2022), Series C (2025), and a 2026 debt facility. AlloFlo Uveo was commercially launched in October 2025 following 3,000+ prior U.S. cases and 100+ trained surgeons, with a development pipeline extending the platform into additional uveoscleral and trabecular indications. AlloFlo Uveo is regulated under Section 361 of the Public Health Services Act. The company employs 51–100 people and is led by CEO Adam Szaronos (appointed February 2025) with founder Dr. Sean Ianchulev serving as Chairman and Chief Medical Officer.

Short descriptiontext

Iantrek is a private medical device company that develops bio-interventional and micro-interventional ophthalmic surgical devices — AlloFlo Uveo, AlloSert Uveo, and C-Rex — for minimally invasive glaucoma surgery targeting uveoscleral and trabecular outflow pathways, sold to ophthalmologists and glaucoma surgeons in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWhite Plains, United States
HQ citystring
White Plains
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimally invasive glaucoma surgery, bio-interventional ophthalmology, uveoscleral outflow devices, ophthalmic surgical instruments, glaucoma bio-tissue implants
Industry2 codes
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAG
Glaucoma Specialists
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Surgical Device Sales
TypeHardware Sales
Description

Iantrek generates revenue through the sale of its commercialized surgical products including AlloFlo Uveo and AlloSert Uveo to ophthalmologists and hospitals. The company operates as a medical device manufacturer selling directly to healthcare providers for use in glaucoma surgical procedures.

iantrekmed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1AlloFlo Uveo
Description

Bio-interventional outflow enhancement device through the uveoscleral pathway, a surgical device for glaucoma treatment.

iantrekmed.com
+2 more records
Core offering1 text field

Iantrek develops and commercializes bio-interventional and micro-interventional ophthalmic surgical devices used by ophthalmologists and glaucoma surgeons in minimally invasive glaucoma surgery. Its core offerings are AlloFlo Uveo (a dual bio-spacer homologous scleral allograft for uveoscleral outflow enhancement), AlloSert Uveo (the surgical delivery instrument for AlloFlo Uveo enabling controlled cyclodialysis), and C-Rex (a single-use Nitinol device for combined canaloplasty and goniotomy). The devices are sold directly to healthcare providers and hospitals in the United States for use in glaucoma surgical procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 32-40% mean IOP reduction at 12-24 months post-surgery
+4 more records
Product overview1 text field

Iantrek is a medical technology company specializing in bio-interventional ophthalmic surgery for glaucoma treatment. The product portfolio centers on three commercially available surgical devices: AlloFlo Uveo (a bio-tissue spacer technology for uveoscleral outflow enhancement), AlloSert Uveo (the delivery instrument for AlloFlo Uveo that enables controlled cyclodialysis), and C-Rex (a micro-interventional device combining canaloplasty and goniotomy using super-elastic Nitinol). AlloFlo Uveo and AlloSert Uveo work together as a system targeting the uveoscleral pathway, while C-Rex targets the trabecular/Schlemm's canal pathway. The pipeline includes AlloSpan Canal and C-Rex Duo for additional glaucoma intervention approaches.

Product and service3 records
1AlloFlo Uveo
CategoryBio-Interventional Ophthalmic Surgical Implant
Description

Bio-tissue spacer technology for uveoscleral outflow enhancement in glaucoma treatment, using acellular homologous scleral allograft tissue to provide scaffolding, bio-reinforcement, and maintenance of the aqueous pathway via dual bio-spacers during cyclodialysis; intended for ophthalmologists and glaucoma surgeons performing MIGS procedures.

2AlloSert Uveo
CategoryOphthalmic Surgical Delivery Instrument
Description

Surgical instrument used for ab-interno construction or modification of a cyclodialysis followed by delivery of bio-tissue/allograft to reinforce and maintain the cyclodialysis cleft; serves as the dedicated delivery system for AlloFlo Uveo and features an ergonomic, ambidextrous design with empty or pre-loaded carrier tip options.

3C-Rex
CategoryMicro-Interventional Ophthalmic Surgical Instrument
Description

Single-use disposable manual ophthalmic surgical instrument for ab-interno transluminal dilation (canaloplasty) and inner wall trabeculotomy (goniotomy); uses super-elastic Nitinol for smooth circumferential tracking up to 360 degrees with clock-hour demarcations for precise filament advancement feedback.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Adam Szaronos
Strategic tierCoreTypeOthersAnnounced on2025-02-04
Description

Adam Szaronos appointed as CEO of Iantrek. Serves as Board Member alongside his executive leadership role.

iantrekmed.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alcon is a global ophthalmic incumbent that markets the Hydrus Microstent and offers a broad surgical glaucoma portfolio. It competes with Iantrek across the MIGS category and brings substantially greater commercial scale and surgeon access.

TypeEmerging player
Description

Belkin Vision has developed the Eagle direct selective laser trabeculoplasty device for glaucoma. It is an emerging player offering a non-incisional interventional approach to the same ophthalmologist customer base Iantrek targets.

TypeEmerging player
Description

Sanoculis developed the MIMS (Minimally Invasive Micro Sclerostomy) procedure for glaucoma. It is an emerging player with a novel surgical approach to the same glaucoma interventional market that Iantrek addresses.

TypeEmerging player
Description

iSTAR Medical developed the MINIject suprachoroidal glaucoma implant, targeting uveoscleral/suprachoroidal outflow. It is an emerging player with direct overlap in the uveoscleral mechanism that Iantrek is also pursuing.

TypeDirect peer
Description

New World Medical develops and distributes surgical devices for glaucoma, including the Kahook Dual Blade for goniotomy. It is a direct peer in interventional glaucoma surgical devices aimed at ophthalmic surgeons.

TypeDirect peer
Description

Sight Sciences markets the OMNI Surgical System, which combines canaloplasty and trabeculotomy for glaucoma treatment. It is a direct peer in MIGS device design, physician call point, and the procedural category Iantrek's C-Rex also targets.

TypeDirect peer
Description

Glaukos pioneered the MIGS category with its iStent devices for trabecular outflow enhancement. It is the most direct competitor to Iantrek in interventional glaucoma surgery, serving the same ophthalmologist customer base with a complementary outflow pathway focus.

TypeBroad incumbent
Description

Bausch + Lomb is a large incumbent ophthalmic medical device and pharmaceutical company with a presence in surgical glaucoma. It is a broad incumbent competing in the same surgeon call point with greater resources and breadth.

TypeDirect peer
Description

Nova Eye Medical markets the iTrack canaloplasty device targeting the trabecular pathway. It is a direct peer in canaloplasty-based MIGS, addressing the same glaucoma surgeon customer with a similar minimally invasive, outflow-focused approach.

TypeEmerging player
Description

MicroOptx is developing novel micro-invasive glaucoma surgical approaches. As a small, early-stage MIGS innovator, it is comparable to Iantrek in stage and category focus on interventional outflow enhancement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iantrek

Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery)iantrekmed.com

Iantrek is a private medical device company that develops bio-interventional and micro-interventional ophthalmic surgical devices — AlloFlo Uveo, AlloSert Uveo, and C-Rex — for minimally invasive glaucoma surgery targeting uveoscleral and trabecular outflow pathways, sold to ophthalmologists and glaucoma surgeons in the United States.

What Iantrek does

Iantrek is a private medical technology company headquartered in White Plains, New York, that develops bio-interventional and micro-interventional ophthalmic surgical devices for the treatment of glaucoma. The company's commercial platform comprises three core products: AlloFlo Uveo, an acellular homologous scleral allograft bio-tissue spacer that reinforces the uveoscleral pathway to enhance aqueous outflow without damaging the conjunctiva or requiring implantable hardware; AlloSert Uveo, an ambidextrous surgical delivery instrument that enables controlled cyclodialysis and precise positioning of the AlloFlo Uveo dual bio-spacers; and C-Rex, a single-use disposable super-elastic Nitinol device for ab-interno transluminal canaloplasty and inner wall trabeculotomy, capable of 360-degree circumferential tracking in a single continuous motion. The platform is supported by the CREST clinical study (500+ eyes across 16 locations, 7 peer-reviewed publications) demonstrating 32–40% mean IOP reduction and 40–64% mean medication reduction at 12–24 months with sub-0.5% clinical hypotony rates.

Iantrek operates as a medical device manufacturer generating revenue through hardware and bio-tissue sales to ophthalmologists and glaucoma surgeons. Pricing is not publicly disclosed; transactions follow the standard institutional medtech quoting model. The go-to-market is enterprise field sales with a 'Contact a Rep' / 'Book a Demo' model targeting hospital and ambulatory surgical center accounts, supplemented by peer-reviewed publications, medical conference presence (ASCRS, AAO, AGS, Glaucoma 360, AECOS), surgeon testimonials, and a 'Find a Surgeon' patient-referral directory. The primary customer segment is MIGS-performing ophthalmologists and glaucoma specialists in the United States.

The company is venture-backed, having raised approximately $100 million cumulatively across a Series A (2020), Series B (2022), Series C (2025), and a 2026 debt facility. AlloFlo Uveo was commercially launched in October 2025 following 3,000+ prior U.S. cases and 100+ trained surgeons, with a development pipeline extending the platform into additional uveoscleral and trabecular indications. AlloFlo Uveo is regulated under Section 361 of the Public Health Services Act. The company employs 51–100 people and is led by CEO Adam Szaronos (appointed February 2025) with founder Dr. Sean Ianchulev serving as Chairman and Chief Medical Officer.

Iantrek firmographics

Firmographics
Name
Iantrek
Legal name
Iantrek, Inc.
Website
https://iantrekmed.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Iantrek is a private medical device company that develops bio-interventional and micro-interventional ophthalmic surgical devices — AlloFlo Uveo, AlloSert Uveo, and C-Rex — for minimally invasive glaucoma surgery targeting uveoscleral and trabecular outflow pathways, sold to ophthalmologists and glaucoma surgeons in the United States.
Ownership category
akta.pro rank

Iantrek industry classification

Industry
Product category
Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery)
NAICS
Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAG
Glaucoma Specialists

Keywords

  • Minimally invasive glaucoma surgery
  • Bio-interventional ophthalmology
  • Uveoscleral outflow devices
  • Ophthalmic surgical instruments
  • Glaucoma bio-tissue implants

Where Iantrek is headquartered

Location

Headquarters

HQ city
White Plains
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Iantrek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Surgical Device Sales: Iantrek generates revenue through the sale of its commercialized surgical products including AlloFlo Uveo and AlloSert Uveo to ophthalmologists and hospitals. The company operates as a medical device manufacturer selling directly to healthcare providers for use in glaucoma surgical procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Iantrek product offering

Product offering

Core offering

Iantrek develops and commercializes bio-interventional and micro-interventional ophthalmic surgical devices used by ophthalmologists and glaucoma surgeons in minimally invasive glaucoma surgery. Its core offerings are AlloFlo Uveo (a dual bio-spacer homologous scleral allograft for uveoscleral outflow enhancement), AlloSert Uveo (the surgical delivery instrument for AlloFlo Uveo enabling controlled cyclodialysis), and C-Rex (a single-use Nitinol device for combined canaloplasty and goniotomy). The devices are sold directly to healthcare providers and hospitals in the United States for use in glaucoma surgical procedures.

Product overview

Iantrek is a medical technology company specializing in bio-interventional ophthalmic surgery for glaucoma treatment. The product portfolio centers on three commercially available surgical devices: AlloFlo Uveo (a bio-tissue spacer technology for uveoscleral outflow enhancement), AlloSert Uveo (the delivery instrument for AlloFlo Uveo that enables controlled cyclodialysis), and C-Rex (a micro-interventional device combining canaloplasty and goniotomy using super-elastic Nitinol). AlloFlo Uveo and AlloSert Uveo work together as a system targeting the uveoscleral pathway, while C-Rex targets the trabecular/Schlemm's canal pathway. The pipeline includes AlloSpan Canal and C-Rex Duo for additional glaucoma intervention approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • AlloFlo Uveo: Bio-interventional outflow enhancement device through the uveoscleral pathway, a surgical device for glaucoma treatment.
  • AlloSert Uveo
  • C-Rex

Products and services

  • AlloFlo Uveo Bio-tissue spacer technology for uveoscleral outflow enhancement in glaucoma treatment, using acellular homologous scleral allograft tissue to provide scaffolding, bio-reinforcement, and maintenance of the aqueous pathway via dual bio-spacers during cyclodialysis; intended for ophthalmologists and glaucoma surgeons performing MIGS procedures.
  • AlloSert Uveo Surgical instrument used for ab-interno construction or modification of a cyclodialysis followed by delivery of bio-tissue/allograft to reinforce and maintain the cyclodialysis cleft; serves as the dedicated delivery system for AlloFlo Uveo and features an ergonomic, ambidextrous design with empty or pre-loaded carrier tip options.
  • C-Rex Single-use disposable manual ophthalmic surgical instrument for ab-interno transluminal dilation (canaloplasty) and inner wall trabeculotomy (goniotomy); uses super-elastic Nitinol for smooth circumferential tracking up to 360 degrees with clock-hour demarcations for precise filament advancement feedback.

Quantifiable outcome

  • 32-40% mean IOP reduction at 12-24 months post-surgery
  • +4 more outcomes

Companies that use Iantrek

Customer profile

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Iantrek technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Iantrek partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Adam SzaronoscoreOthers · 4 February 2025Adam Szaronos appointed as CEO of Iantrek. Serves as Board Member alongside his executive leadership role.

Scale indicators5 records

Recent moves6 records

Expansion highlights3 records

Iantrek competitors and assessment

Company assessment

Broad incumbents

  • Alcon: Alcon is a global ophthalmic incumbent that markets the Hydrus Microstent and offers a broad surgical glaucoma portfolio. It competes with Iantrek across the MIGS category and brings substantially greater commercial scale and surgeon access.
  • Bausch + Lomb: Bausch + Lomb is a large incumbent ophthalmic medical device and pharmaceutical company with a presence in surgical glaucoma. It is a broad incumbent competing in the same surgeon call point with greater resources and breadth.

Emerging players

  • Belkin Vision: Belkin Vision has developed the Eagle direct selective laser trabeculoplasty device for glaucoma. It is an emerging player offering a non-incisional interventional approach to the same ophthalmologist customer base Iantrek targets.
  • Sanoculis: Sanoculis developed the MIMS (Minimally Invasive Micro Sclerostomy) procedure for glaucoma. It is an emerging player with a novel surgical approach to the same glaucoma interventional market that Iantrek addresses.
  • iSTAR Medical: iSTAR Medical developed the MINIject suprachoroidal glaucoma implant, targeting uveoscleral/suprachoroidal outflow. It is an emerging player with direct overlap in the uveoscleral mechanism that Iantrek is also pursuing.
  • MicroOptx: MicroOptx is developing novel micro-invasive glaucoma surgical approaches. As a small, early-stage MIGS innovator, it is comparable to Iantrek in stage and category focus on interventional outflow enhancement.

Direct peers

  • New World Medical: New World Medical develops and distributes surgical devices for glaucoma, including the Kahook Dual Blade for goniotomy. It is a direct peer in interventional glaucoma surgical devices aimed at ophthalmic surgeons.
  • Sight Sciences: Sight Sciences markets the OMNI Surgical System, which combines canaloplasty and trabeculotomy for glaucoma treatment. It is a direct peer in MIGS device design, physician call point, and the procedural category Iantrek's C-Rex also targets.
  • Glaukos Corporation: Glaukos pioneered the MIGS category with its iStent devices for trabecular outflow enhancement. It is the most direct competitor to Iantrek in interventional glaucoma surgery, serving the same ophthalmologist customer base with a complementary outflow pathway focus.
  • Nova Eye Medical: Nova Eye Medical markets the iTrack canaloplasty device targeting the trabecular pathway. It is a direct peer in canaloplasty-based MIGS, addressing the same glaucoma surgeon customer with a similar minimally invasive, outflow-focused approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Iantrek social profiles

Digital presence

Iantrek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iantrek leadership team

Management profile

Number of profiles

Profiles3 records

Iantrek funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iantrek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iantrek

What does Iantrek do?

Iantrek develops and commercializes bio-interventional and micro-interventional ophthalmic surgical devices used by ophthalmologists and glaucoma surgeons in minimally invasive glaucoma surgery. Its core offerings are AlloFlo Uveo (a dual bio-spacer homologous scleral allograft for uveoscleral outflow enhancement), AlloSert Uveo (the surgical delivery instrument for AlloFlo Uveo enabling controlled cyclodialysis), and C-Rex (a single-use Nitinol device for combined canaloplasty and goniotomy). The devices are sold directly to healthcare providers and hospitals in the United States for use in glaucoma surgical procedures.

Is Iantrek a public or private company?

Iantrek is a private company. It is classified as venture growth investor backed and is currently operating.

When was Iantrek founded?

Iantrek was founded in 2019. It employs 51 to 100 people.

Where is Iantrek based?

Iantrek is headquartered in White Plains, United States, in the North America region.

How does Iantrek make money?

One revenue line is on record: surgical Device Sales.

Who are Iantrek's main competitors?

Broad incumbents on record are Alcon and Bausch + Lomb. Emerging players are Belkin Vision, Sanoculis, iSTAR Medical and MicroOptx. Direct peers are New World Medical, Sight Sciences, Glaukos Corporation and Nova Eye Medical.

Does Iantrek have an API?

No public API is recorded for Iantrek.

What industry is Iantrek in?

Iantrek's product category is Ophthalmic Surgical Devices (Minimally Invasive Glaucoma Surgery). Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAKAKAG, Glaucoma Specialists. Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesIantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatmentIantrek, Inc. announced one-year results from the CREST Registry, showing that its bio-interventional glaucoma treatment significantly reduced intraocular pressure and medication usage in patients with open-angle glaucoma. The study reported a 39.7% mean IOP reduction for high-pressure patients and an 81.9% success rate in achieving target pressure without additional medication, while maintaining a favorable safety profile with no vision-threatening adverse events.Ophthalmology TimesQ&A: What’s in the glaucoma treatment pipeline?Dr. James Tsai outlines the current glaucoma treatment pipeline, highlighting clinical trials for devices like Iantrek's CycloPen and drugs from QLARIS Bio and Ophthalmic Therapeutic Innovation aimed at reducing intraocular pressure. The article also notes progress in surgical technologies and the potential near-term FDA approval for SmartLens Inc.'s smart contact lens for continuous eye pressure monitoring.Pulse 2.0Iantrek Secures $30 Million In Growth Capital From Trinity Capital To Expand Ophthalmic Surgery PlatformIantrek, a medical technology company focused on bio-interventional ophthalmic surgery, has secured $30 million in growth capital from Trinity Capital, a Phoenix-based alternative asset manager. The debt facility will fund commercial expansion, pipeline development, manufacturing scale-up, and market access initiatives for its surgical platform, including the AlloFlo Uveo product launched in October 2025 and the upcoming AlloSpan Canal. The financing follows a 2025 Series C raise that included lead equity investors USVP, Sectoral, aMoon, and Visionary Ventures.BioWorldFinancings for April 29, 2026BioWorld reported financings for April 29, 2026, covering biopharma and med-tech companies. The listed companies include Aventera, Climb, Coultreon, Fathom, Iantrek, Lighthouse, Mbiomics, Modus, and Quest. The full story requires subscription or sign-in.FinSMEsIantrek Receives $30M in Growth Capital From Trinity CapitalIantrek, a NYC-based medical technology company, received $30M in growth capital from Trinity Capital. The debt facility follows a Series C raise in 2025 and will fund development and adoption of AlloFlo Uveo, its lead commercial technology, and new bio-interventional innovations.citybizTrinity Capital Commits $30 Million Growth Facility to Ophthalmic Medtech Company IantrekTrinity Capital Inc. has committed $30 million in growth capital to Iantrek, a medical technology company developing bio-interventional ophthalmic surgery solutions for glaucoma treatment. The financing will support Iantrek's commercial expansion, manufacturing scale-up, and continued development of its product pipeline including AlloFlo Uveo. The investment reflects institutional interest in medtech companies advancing minimally invasive surgical solutions for chronic eye diseases.PR NewswireTrinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product PipelineTrinity Capital Inc. announced a $30 million growth capital commitment to Iantrek, a medical technology company specializing in bio-interventional ophthalmic surgery for glaucoma treatment. The funding will support Iantrek's commercial expansion, product pipeline development, manufacturing scaling, and market access initiatives for its lead technology AlloFlo Uveo. The debt facility follows Iantrek's successful Series C raise in 2025 and positions the company to accelerate adoption of its surgical platform.Stock TitanTrinity Capital commits $30M debt facility to IantrekTrinity Capital Inc. announced a $30 million debt facility commitment to Iantrek, a medical technology company specializing in bio-interventional ophthalmic surgery for glaucoma treatment. The growth capital will support Iantrek's commercial expansion, product pipeline advancement, manufacturing scale-up, and market access initiatives. This funding follows Iantrek's successful Series C raise in 2025 and positions the company to accelerate adoption of its AlloFlo Uveo lead technology.TrinitycapitalTrinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product PipelineTrinity Capital committed $30 million in growth capital to Iantrek, a medical technology company developing bio-interventional ophthalmic surgery technologies for glaucoma. The funding will support commercial expansion, pipeline development, and manufacturing scaling, following Iantrek's 2025 series C raise.